BioIVT, a provider of biospecimens and related services, has acquired Ascendance Biotechnology, Inc. Ascendance was formed as a multinational cell-based assay company in November 2015 through the merger of Hepregen Corporation and the ESI BIO products division of BioTime Inc. As a result of the acquisition, BioIVT has added Hepregen’s HepatoPac, HepatoMune and HepatoStem liver cell and stem cell product lines to its drug safety testing and toxicology portfolios.
Hepregen’s products employ a patented cell micropatterning technology in which different cell types are plated on industry-standard micro-well plates in proprietary patterns. The plates provide in-vitro cellular co-cultures that have a longer life and improved function. The HepatoPac products feature primary hepatocytes and fibroblasts that have been micro-patterned to create hepatocyte islands surrounded by supportive stromal cells. This approach closely mimics the function of a human liver and allows the hepatocytes to maintain normal metabolic activity for several weeks.
With HepatoMune, the micro-patterned primary hepatocytes and fibroblasts are supplemented with primary Kupffer cells, creating highly functional human liver tissue that models inflammation-mediated hepatotoxicity. HepatoMune tri-cultures remain viable for at least ten days, retaining both liver cell and Kupffer cell functionality, and can be used for predicting clinical outcomes. HepatoStem applies the same micro-patterning technology to stem cells.
For further information about BioIVT visit www.bioivt.com
Latest from Tom Mulligan
- SGS’s first malaria human challenge trial will take place in Belgium this month
- TC BioPharm creates allogeneic cell banks for CAR-T cancer therapy products
- Horizon Discovery extends CRISPR Screening Service to primary human T cells
- TrakCel and The Quick Life Science Group partner on supply chain IT solution for cell and gene therapies
- Almac Group extends personalised cancer vaccine production facilities
- Cobra Biologics appoints Dr Darrell Sleep as Director of Innovation
- Phico Therapeutics appoints financial director and two non-executive directors
- Evonetix appoints Stephanie Brooking as Head of Product Management
- Bio-Rad publishes new findings on generation and characterisation of drug-target-complex-specific antibodies
- Expedeon licenses Lightning-Link rapid biotinylation technology to Cell Guidance Systems